Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Andrea Decensi
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Concepts & Ideas
Procedures
Physiology
Geographic Areas
Sign-in to see full Profile
Network (preview)
31
Bonanni, Bernardo
29
Torrisi, Rosalba
28
Guerrieri-Gonzaga, Aliana
21
Johansson, Harriet
21
Costa, Alberto
20
Formelli, Franca
19
Veronesi, Umberto
18
Robertson, Chris
17
Boccardo, Francesco
15
Cazzaniga, Massimiliano
13
De Palo, Giuseppe
12
Baglietto, Laura
12
Sandri, Maria Teresa
12
Serrano, Davide
11
Fontana, Vincenzo
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Andrea Decensi (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Bonanni Bernardo; Serrano Davide; Gandini Sara; Guerrieri-Gonzaga Aliana; Johansson Harriet; Macis Debora; Cazzaniga Massimiliano; Luini Alberto; Cassano Enrico; Oldani Sabina; Lien Ernst A; Pelosi Giuseppe; Decensi Andrea
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7053-60.
-
2009: Puntoni Matteo; Decensi Andrea
The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():346-54.
-
2009: Decensi Andrea; Robertson Chris; Guerrieri-Gonzaga Aliana; Serrano Davide; Cazzaniga Massimiliano; Mora Serena; Gulisano Marcella; Johansson Harriet; Galimberti Viviana; Cassano Enrico; Moroni Simona M; Formelli Franca; Lien Ernst A; Pelosi Giuseppe; Johnson Karen A; Bonanni Bernardo
Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3749-56.
-
2009: Cazzaniga Massimiliano; Decensi Andrea; Bonanni Bernardo; Luini Alberto; Gentilini Oreste
Biomarkers for risk assessment and prevention of breast cancer.
Current cancer drug targets 2009;9(4):482-99.
-
2009: Zanardi Silvia; Puntoni Matteo; Maffezzini Massimo; Bandelloni Roberto; Mori Marco; Argusti Alessandra; Campodonico Fabio; Turbino Laura; Branchi Daniela; Montironi Rodolfo; Decensi Andrea
Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
Cancer prevention research (Philadelphia, Pa.) 2009;2(4):377-84.
-
2009: Cazzaniga Massimiliano; Gheit Tarik; Casadio Chiara; Khan Noureen; Macis Debora; Valenti Francesco; Miller Mara Jo; Sylla Bakary S; Akiba Suminori; Bonanni Bernardo; Decensi Andrea; Veronesi Umberto; Tommasino Massimo
Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis.
Breast cancer research and treatment 2009;114(3):599-605.
-
2009: Guerrieri-Gonzaga Aliana; Botteri Edoardo; Rotmensz Nicole; Bassi Fabio; Intra Mattia; Serrano Davide; Renne Giuseppe; Luini Alberto; Cazzaniga Massimiliano; Goldhirsch Aaron; Colleoni Marco; Viale Giuseppe; Ivaldi Giovanni; Bagnardi Vincenzo; Lazzeroni Matteo; Decensi Andrea; Veronesi Umberto; Bonanni Bernardo
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.
The oncologist 2009;14(3):201-12.
-
2009: Cazzaniga Massimiliano; Bonanni Bernardo; Guerrieri-Gonzaga Aliana; Decensi Andrea
Is it time to test metformin in breast cancer clinical trials?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(3):701-5.
-
2009: Puntoni Matteo; Bonanni Bernardo; Decensi Andrea
Dietary changes after breast cancer in women without hot flashes: a simple and inexpensive way to target tumor and host?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(3):323-5.
-
2008: Johansson Harriet; Gandini Sara; Guerrieri-Gonzaga Aliana; Iodice Simona; Ruscica Massimiliano; Bonanni Bernardo; Gulisano Marcella; Magni Paolo; Formelli Franca; Decensi Andrea
Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.
Cancer research 2008;68(22):9512-8.
-
2008: Puntoni M; Marra D; Zanardi S; Decensi A
Inflammation and cancer prevention.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii225-9.
-
2008: Rondanina Gabriella; Puntoni Matteo; Severi Gianluca; Varricchio Clara; Zunino Anna; Feroce Irene; Bonanni Bernardo; Decensi Andrea
Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1537-43.
-
2008: Johansson Harriet; Gandini Sara; Bonanni Bernardo; Mariette Frederique; Guerrieri-Gonzaga Aliana; Serrano Davide; Cassano Enrico; Ramazzotto Francesca; Baglietto Laura; Sandri Maria Teresa; Decensi Andrea
Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
Breast cancer research and treatment 2008;108(1):57-67.
-
2008: Serrano Davide; Gandini Sara; Mariani Luigi; Bonanni Bernardo; Santinelli Alfredo; Guerrieri-Gonzaga Aliana; Pelosi Giuseppe; Cassano Enrico; Montironi Rodolfo; Decensi Andrea
Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users.
Breast (Edinburgh, Scotland) 2008;17(1):91-7.
-
2007: Macis Debora; Maisonneuve Patrick; Johansson Harriet; Bonanni Bernardo; Botteri Edoardo; Iodice Simona; Santillo Barbara; Penco Silvana; Gucciardo Giacomo; D'Aiuto Giuseppe; Rosselli Del Turco Marco; Amadori Marinella; Costa Alberto; Decensi Andrea
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.
Breast cancer research and treatment 2007;106(2):263-71.
-
2007: Decensi Andrea; Gandini Sara; Serrano Davide; Cazzaniga Massimiliano; Pizzamiglio Maria; Maffini Fausto; Pelosi Giuseppe; Daldoss Cristina; Omodei Umberto; Johansson Harriet; Macis Debora; Lazzeroni Matteo; Penotti Mauro; Sironi Laura; Moroni Simona; Bianco Vanda; Rondanina Gabriella; Gjerde Jennifer; Guerrieri-Gonzaga Aliana; Bonanni Bernardo
Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4201-9.
-
2007: Puntoni Matteo; Zanardi Silvia; Branchi Daniela; Bruno Silvia; Curotto Antonio; Varaldo Marco; Bruzzi Paolo; Decensi Andrea
Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):979-83.
-
2007: Veronesi Umberto; Maisonneuve Patrick; Rotmensz Nicole; Bonanni Bernardo; Boyle Peter; Viale Giuseppe; Costa Alberto; Sacchini Virgilio; Travaglini Roberto; D'Aiuto Giuseppe; Oliviero Pasquale; Lovison Francesco; Gucciardo Giacomo; del Turco Marco Rosselli; Muraca Maria Grazia; Pizzichetta Maria Antonietta; Conforti Serafino; Decensi Andrea;
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Journal of the National Cancer Institute 2007;99(9):727-37.
-
2007: Veronesi Umberto; Maisonneuve Patrick; Decensi Andrea
Tamoxifen: an enduring star.
Journal of the National Cancer Institute 2007;99(4):258-60.
-
2007: Decensi Andrea; Zanardi Silvia; Argusti Alessandra; Bonanni Bernardo; Costa Alberto; Veronesi Umberto
Fenretinide and risk reduction of second breast cancer.
Nature clinical practice. Oncology 2007;4(2):64-5.
-
2006: Colombo Nicoletta; Formelli Franca; Cantù Maria Grazia; Parma Gabriella; Gasco Milena; Argusti Alessandra; Santinelli Alfredo; Montironi Rodolfo; Cavadini Elena; Baglietto Laura; Guerrieri-Gonzaga Aliana; Viale Giuseppe; Decensi Andrea
A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(10):1914-9.
-
2006: Bonanni Bernardo; Macis Debora; Maisonneuve Patrick; Johansson Harriet A; Gucciardo Giacomo; Oliviero Pasquale; Travaglini Roberto; Muraca Maria G; Rotmensz Nicole; Veronesi Umberto; Decensi Andrea U
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3708-9; author reply 3709.
-
2006: Serrano Davide; Mariani Luigi; Mora Serena; Guerrieri-Gonzaga Aliana; Cazzaniga Massimiliano; Daldoss Cristina; Ramazzotto Francesca; Feroce Irene; Decensi Andrea; Bonanni Bernardo
Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Maturitas 2006;55(1):69-75.
-
2006: Cazzaniga Massimiliano; Severi Gianluca; Casadio Chiara; Chiapparini Laura; Veronesi Umberto; Decensi Andrea
Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(7):1311-5.
-
2006: Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro M G; Costa A; Marubini E; Sporn M B; De Palo G
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(7):1065-71.
-
2006: Johansson Harriet; Bonanni Bernardo; Mariette Frederique; Cazzaniga Massimiliano; Baglietto Laura; Guerrieri-Gonzaga Aliana; Sandri Maria Teresa; Luini Alberto; Pelosi Giuseppe; Decensi Andrea
Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
Breast cancer research and treatment 2006;98(2):167-72.
-
2006: Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Clinical trials with retinoids for breast cancer chemoprevention.
Endocrine-related cancer 2006;13(1):51-68.
-
2006: Guerrieri-Gonzaga Aliana; Robertson Chris; Bonanni Bernardo; Serrano Davide; Cazzaniga Massimiliano; Mora Serena; Gulisano Marcella; Johansson Harriet; Formelli Franca; Intra Mattia; Latronico Antuono; Franchi Dorella; Pelosi Giuseppe; Johnson Karen; Decensi Andrea
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):129-35.
-
2005: Gasco Milena; Argusti Alessandra; Bonanni Bernardo; Decensi Andrea
SERMs in chemoprevention of breast cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(13):1980-9.
-
2005: Bruno Savino; Maisonneuve Patrick; Castellana Paola; Rotmensz Nicole; Rossi Sonia; Maggioni Marco; Persico Marcello; Colombo Alberto; Monasterolo Franco; Casadei-Giunchi Donata; Desiderio Franco; Stroffolini Tommaso; Sacchini Virgilio; Decensi Andrea; Veronesi Umberto
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
BMJ (Clinical research ed.) 2005;330(7497):932.
-
2005: Serrano Davide; Baglietto Laura; Johansson Harriet; Mariette Frederique; Torrisi Rosalba; Onetto Marina; Paganuzzi Michela; Decensi Andrea
Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):2083-8.
-
2005: Decensi Andrea; Maisonneuve Patrick; Rotmensz Nicole; Bettega Donato; Costa Alberto; Sacchini Virgilio; Salvioni Alessandro; Travaglini Roberto; Oliviero Pasquale; D'Aiuto Giuseppe; Gulisano Marcella; Gucciardo Giacomo; del Turco Marco Rosselli; Pizzichetta Maria Antonietta; Conforti Serafino; Bonanni Bernardo; Boyle Peter; Veronesi Umberto;
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.
Circulation 2005;111(5):650-6.
-
2004: Serrano D; Lazzeroni M; Decensi A
Chemoprevention of colorectal cancer: an update.
Techniques in coloproctology 2004;8 Suppl 2():s248-52.
-
2004: Johansson Harriet; Baglietto Laura; Guerrieri-Gonzaga Aliana; Bonanni Bernardo; Mariette Frederique; Macis Debora; Serrano Davide; Sandri Maria Teresa; Decensi Andrea
Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
Breast cancer research and treatment 2004;88(1):63-73.
-
2004: Decensi Andrea; Bonanni Bernardo; Baglietto Laura; Guerrieri-Gonzaga Aliana; Ramazzotto Francesca; Johansson Harriet; Robertson Chris; Marinucci Irene; Mariette Frederique; Sandri Maria Teresa; Daldoss Cristina; Bianco Vanda; Buttarelli Marco; Cazzaniga Massimiliano; Franchi Dorella; Cassano Enrico; Omodei Umberto
A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4389-97.
-
2004: Kisanga Elton R; Gjerde Jennifer; Guerrieri-Gonzaga Aliana; Pigatto Francesca; Pesci-Feltri Adriana; Robertson Chris; Serrano Davide; Pelosi Giuseppe; Decensi Andrea; Lien Ernst A
Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2336-43.
-
2004: Serrano Davide; Perego Elisa; Costa Alberto; Decensi Andrea
Progress in chemoprevention of breast cancer.
Critical reviews in oncology/hematology 2004;49(2):109-17.
-
2003: Serrano Davide; Bonanni Bernardo; Cazzaniga Massimiliano; Galli Arianna; Gonzaga Aliana Guerrieri; Decensi Andrea
Pharmacological prevention of breast cancer: quo vadis?
Breast (Edinburgh, Scotland) 2003;12(6):379-86.
-
2003: Decensi Andrea; Veronesi Umberto; Miceli Rosalba; Johansson Harriet; Mariani Luigi; Camerini Tiziana; Di Mauro Maria Gaetana; Cavadini Elena; De Palo Giuseppe; Costa Alberto; Perloff Marjorie; Malone Winfred F; Formelli Franca
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4722-9.
-
2003: Bonanni B; Johansson H; Gandini S; Guerrieri-Gonzaga A; Sandri M T; Mariette F; Lien E A; Decensi A
Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women.
Journal of thrombosis and haemostasis : JTH 2003;1(10):2149-52.
-
2003: Garaventa Alberto; Luksch Roberto; Lo Piccolo Maria Serena; Cavadini Elena; Montaldo Paolo G; Pizzitola Maria Rosa; Boni Luca; Ponzoni Mirco; Decensi Andrea; De Bernardi Bruno; Bellani Franca Fossati; Formelli Franca
Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2032-9.
-
2003: Decensi Andrea; Robertson Chris; Viale Giuseppe; Pigatto Francesca; Johansson Harriet; Kisanga Elton R; Veronesi Paolo; Torrisi Rosalba; Cazzaniga Massimiliano; Mora Serena; Sandri Maria T; Pelosi Giuseppe; Luini Alberto; Goldhirsch Aron; Lien Ernst A; Veronesi Umberto
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
Journal of the National Cancer Institute 2003;95(11):779-90.
-
2003: Decensi Andrea; Serrano Davide; Bonanni Bernardo; Cazzaniga Massimiliano; Guerrieri-Gonzaga Aliana
Breast cancer prevention trials using retinoids.
Journal of mammary gland biology and neoplasia 2003;8(1):19-30.
-
2003: Veronesi Umberto; Maisonneuve Patrick; Rotmensz Nicole; Costa Alberto; Sacchini Virgilio; Travaglini Roberto; D'Aiuto Giuseppe; Lovison Francesco; Gucciardo Giacomo; Muraca Maria Grazia; Pizzichetta Maria Antonietta; Conforti Serafino; Decensi Andrea; Robertson Chris; Boyle Peter;
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Journal of the National Cancer Institute 2003;95(2):160-5.
-
2003: Decensi Andrea; Galli Arianna; Veronesi Umberto
HRT opposed to low-dose tamoxifen (HOT study): rationale and design.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;163():104-11; discussion 264-6.
-
2002: Decensi Andrea
[Risks and benefits of hormone replacement therapy: clinical considerations and research implications]
Epidemiologia e prevenzione 2002;26(6):280-2.
-
2002: Rotmensz N; Decensi A; Maisonneuve P; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Lovison F; Gucciardo G; Muraca M G; Pizzichetta M A; Conforti S; Robertson C; Boyle P; Veronesi U
Rationale for a study adding tamoxifen to HRT.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 6():S22-3.
-
2002: Decensi Andrea; Omodei Umberto; Robertson Chris; Bonanni Bernardo; Guerrieri-Gonzaga Aliana; Ramazzotto Francesca; Johansson Harriet; Mora Serena; Sandri Maria Teresa; Cazzaniga Massimiliano; Franchi Massimo; Pecorelli Sergio
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
Circulation 2002;106(10):1224-8.
-
2002: De Palo Giuseppe; Mariani Luigi; Camerini Tiziana; Marubini Ettore; Formelli Franca; Pasini Barbara; Decensi Andrea; Veronesi Umberto
Effect of fenretinide on ovarian carcinoma occurrence.
Gynecologic oncology 2002;86(1):24-7.
-
2001: Guerrieri-Gonzaga A; Galli A; Rotmensz N; Decensi A
The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives.
Annals of the New York Academy of Sciences 2001;949():113-22.
-
2001: Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
British journal of cancer 2001;85(12):1838-41.
-
2001: Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro M G; Barreca A; Gonzaga A G; Diani S; Sandri M T; De Palo G; Formelli F
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(10):1047-53.
-
2001: Bonanni B; Johansson H; Gandini S; Guerrieri-Gonzaga A; Torrisi R; Sandri M T; Cazzaniga M; Mora S; Robertson C; Lien E A; Decensi A
Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women.
Breast cancer research and treatment 2001;69(1):21-7.
-
2001: Guerrieri-Gonzaga A; Baglietto L; Johansson H; Bonanni B; Robertson C; Sandri M T; Canigiula L; Lampreda C; Diani S; Lien E A; Decensi A
Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(9):967-70.
-
2001: Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro M G; Decensi A; Costa A; Veronesi U
Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1664-70.
-
2001: Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
Chemoprevention of breast cancer with fenretinide.
Drugs 2001;61(7):909-18.
-
2000: Decensi A; Torrisi R; Bruno S; Costantini M; Curotto A; Nicolò G; Malcangi B; Baglietto L; Bruttini G P; Gatteschi B; Rondanina G; Varaldo M; Perloff M; Malone W F; Bruzzi P
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(10):1071-8.
-
2000: Decensi A; Bonanni B; Rotmensz N; Robertson C; Guerrieri-Gonzaga A; Mora S; Diani S; Cazzaniga M; Costa A
Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 4():S50-1.
-
2000: Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
International journal of cancer. Journal international du cancer 2000;87(4):601-5.
-
2000: Torrisi R; Decensi A
Fenretinide and cancer prevention.
Current oncology reports 2000;2(3):263-70.
-
2000: Decensi A; Costa A
Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(6):694-709.
-
2000: Veronesi U; De Palo G; Marubini E; Costa A; Mariani L; Formelli F; Decensi A
Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Journal of the National Cancer Institute 2000;92(3):274; author reply 274-5.
-
2000: Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga A G; Pasquetti W; Robertson C; Decensi A
Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Cancer detection and prevention 2000;24(4):369-75.
-
2000: Decensi A; Bonanni B; Guerrieri-Gonzaga A; Torrisi R; Manetti L; Robertson C; De Palo G; Formelli F; Costa A; Veronesi U
Chemoprevention of breast cancer: the Italian experience.
Journal of cellular biochemistry. Supplement 2000;34():84-96.
-
1999: Bruno S; Torrisi R; Costantini M; Baglietto L; Fontana V; Gatteschi B; Melioli G; Nicolo G; Curotto A; Malcangi B; Bruttini G P; Varaldo M; Bruzzi P; Decensi A
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.
Journal of cellular biochemistry 1999;76(2):311-21.
-
1999: Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco M R; Di Mauro M G; Muraca M G; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone W F; Sporn M B
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Journal of the National Cancer Institute 1999;91(21):1847-56.
-
1999: Decensi A; Gandini S; Guerrieri-Gonzaga A; Johansson H; Manetti L; Bonanni B; Sandri M T; Barreca A; Costa A; Robertson C; Lien E A
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2633-8.
-
1999: Decensi A; Robertson C; Ballardini B; Paggi D; Guerrieri-Gonzaga A; Bonanni B; Manetti L; Johansson H; Barreca A; Bettega D; Costa A
Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.
European journal of cancer (Oxford, England : 1990) 1999;35(4):596-600.
-
1999: Decensi A; Torrisi R; Gozza A; Severi G; Bertelli G; Fontana V; Pensa F; Carozzo L; Traverso A; Milone S; Dini D; Costa A
Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer.
Breast cancer research and treatment 1999;53(2):145-51.
-
1998: Decensi A; Bonanni B; Guerrieri-Gonzaga A; Gandini S; Robertson C; Johansson H; Travaglini R; Sandri M T; Tessadrelli A; Farante G; Salinaro F; Bettega D; Barreca A; Boyle P; Costa A; Veronesi U
Biologic activity of tamoxifen at low doses in healthy women.
Journal of the National Cancer Institute 1998;90(19):1461-7.
-
1998: Decensi A; Robertson C; Rotmensz N; Severi G; Maisonneuve P; Sacchini V; Boyle P; Costa A; Veronesi U
Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.
British journal of cancer 1998;78(5):572-8.
-
1998: Decensi A; Torrisi R; Fontana V; Barreca A; Ponzani P; Pensa F; Parodi S; Costa A
Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial.
European journal of cancer (Oxford, England : 1990) 1998;34(7):999-1003.
-
1998: Cattaneo M; Baglietto L; Zighetti M L; Bettega D; Robertson C; Costa A; Mannucci P M; Decensi A
Tamoxifen reduces plasma homocysteine levels in healthy women.
British journal of cancer 1998;77(12):2264-6.
-
1998: Torrisi R; Parodi S; Fontana V; Pensa F; Casella C; Barreca A; De Palo G; Costa A; Decensi A
Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
International journal of cancer. Journal international du cancer 1998;76(6):787-90.
-
1998: Fontana V; Decensi A; Orengo M A; Parodi S; Torrisi R; Puntoni R
Socioeconomic status and survival of gastric cancer patients.
European journal of cancer (Oxford, England : 1990) 1998;34(4):537-42.
-
1998: Costa A; Bonanni B; Manetti L; Guerrieri Gonzaga A; Torrisi R; Decensi A
Prevention of breast cancer: focus on chemoprevention.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;152():11-21.
-
1997: De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro M G; Attili A; Maltoni C; Del Turco M R; Decensi A; D'Aiuto G; Veronesi U
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
Tumori 1997;83(6):884-94.
-
1997: Decensi A; Fontana V; Fioretto M; Rondanina G; Torrisi R; Orengo M A; Costa A
Long-term effects of fenretinide on retinal function.
European journal of cancer (Oxford, England : 1990) 1997;33(1):80-4.
-
1996: Decensi A; Fontana V; Bruno S; Gustavino C; Gatteschi B; Costa A
Effect of tamoxifen on endometrial proliferation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):434-40.
-
1996: Bruno S; Machí A M; Semino C; Meta M; Ponte M; Varaldo M; Curotto A; Ferlazzo G; Decensi A; Melioli G
Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer.
Cancer immunology, immunotherapy : CII 1996;42(1):47-54.
-
1996: Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
Chemoprevention of breast cancer with fenretinide.
IARC scientific publications 1996;(136):87-94.
-
1995: Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
Annals of the New York Academy of Sciences 1995;768():148-62.
-
1995: Torrisi R; Pensa F; Fontana V; Costa A; Decensi A
The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.
European journal of cancer (Oxford, England : 1990) 1995;31A(3):420-1.
-
1994: Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1994;3(6):507-10.
-
1994: Decensi A; Curotto A; Bruno S; Costantini M; Torrisi R; Gatteschi B; Cussotto M; Pizzorno R; Quattrini S; Repetto U
DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1994;3(4):377-9.
-
1994: Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Cancer research 1994;54(7 Suppl):2032s-2037s.
-
1994: Decensi A; Torrisi R; Fontana V
Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
British journal of cancer 1994;69(3):617-9.
-
1994: Decensi A; Bruno S; Costantini M; Torrisi R; Curotto A; Gatteschi B; Nicolò G; Polizzi A; Perloff M; Malone W F
Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.
Journal of the National Cancer Institute 1994;86(2):138-40.
-
1994: Decensi A; Torrisi R; Polizzi A; Gesi R; Brezzo V; Rolando M; Rondanina G; Orengo M A; Formelli F; Costa A
Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.
Journal of the National Cancer Institute 1994;86(2):105-10.
-
1994: Boccardo F; Cannata D; Rubagotti A; Guarneri D; Decensi A; Canobbio L; Curotto A; Martorana G; Pegoraro C; Selvaggi F
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):7-13.
-
1994: Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
The Prostate 1994;24(1):17-23.
-
1994: Decensi A; Bruno S; Torrisi R; Parodi S; Polizzi A
Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(12):1909-10.
-
1993: Torrisi R; Pensa F; Orengo M A; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Cancer research 1993;53(20):4769-71.
-
1993: Decensi A; Torrisi R; Fontana V; Marroni P; Padovani P; Guarneri D; Minuto F; Boccardo F
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer.
Acta endocrinologica 1993;129(4):315-21.
-
1993: Boccardo F; Pace M; Rubagotti A; Guarneri D; Decensi A; Oneto F; Martorana G; Giuliani L; Selvaggi F; Battaglia M
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1088-93.
-
1993: Decensi A; Formelli F; Torrisi R; Costa A
Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
Journal of cellular biochemistry. Supplement 1993;17G():226-33.
-
1993: Canobbio L; Guarneri D; Miglietta L; Decensi A; Oneto F; Boccardo F
Carboplatin in advanced hormone refractory prostatic cancer patients.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2094-6.
-
1992: Boccardo F; Guarneri D; Pace M; Decensi A; Oneto F; Martorana G
Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients.
Tumori 1992;78(2):137-9.
-
1992: Decensi A; Bruno S; Giaretti W; Torrisi R; Curotto A; Gatteschi B; Geido E; Polizzi A; Costantini M; Bruzzi P
Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.
Journal of cellular biochemistry. Supplement 1992;16I():139-47.
-
1991: Decensi A U; Boccardo F; Guarneri D; Positano N; Paoletti M C; Costantini M; Martorana G; Giuliani L
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
The Journal of urology 1991;146(2):377-81.
-
1991: Decensi A; Guarneri D; Paoletti M C; Lalanne J M; Merlo F; Boccardo F
Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
European journal of cancer (Oxford, England : 1990) 1991;27(9):1100-4.
-
1991: Canobbio L; Boccardo F; Guarneri D; Calabria C; Decensi A; Curotto A; Martorana G; Giuliani L
Phase II study of navelbine in advanced renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 1991;27(6):804-5.
-
1991: Boccardo F; Decensi A U; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso M P; Giuliani L; Santi L; Periti P
Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Cancer detection and prevention 1991;15(6):501-3.
-
1990: Boccardo F; Canobbio L; Resasco M; Decensi A U; Pastorino G; Brema F
Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.
Journal of cancer research and clinical oncology 1990;116(5):503-6.
-
1990: Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
European urology 1990;18 Suppl 3():48-53.
-
1989: Decensi A U; Guarneri D; Marroni P; Di Cristina L; Paganuzzi M; Boccardo F
Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men.
The Journal of urology 1989;142(5):1235-8.
-
1988: Boccardo F; Decensi A; Guarneri D; Rubagotti A; Martorana G; Giberti C; Cerruti G B; Tani F; Zanollo A; Germinale T
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial.
American journal of clinical oncology 1988;11 Suppl 2():S129-31.
-
1987: Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti G B; Tani F; Zanollo A
Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
The Prostate 1987;11(3):243-55.
Sign-in to see more
